Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
When Risk Management Becomes Risk Avoidance
A better way to manage Legal and Compliance in biotechnology: how “How can we accomplish this appropriately?” can become “Why take the risk?”—and why emerging biotech leadership must keep that balance.
Read ArticleHas Your Biotech Earned the Right to Scale?
Growth is often treated as success in biotech. The better question is whether the company has generated enough evidence to earn the next level of investment—and scale as uncertainty is reduced.
Read ArticleRare Disease Market Size: Why Prevalence Is Not the Commercial Opportunity
Prevalence describes how many people may have a rare disease. Commercial opportunity depends on diagnosis, reach, access and treatment initiation.
Read ArticleBuild or Outsource? Designing the First Commercial Organization for an Emerging Biotech
Decide what to build internally and what to outsource when designing an emerging biotechnology company's first commercial organization.
Read ArticleHow Medical Affairs and Commercial Teams Should Prepare Together for Launch
Physicians experience one company. Medical Affairs and Commercial must align around the same market reality, evidence needs and launch governance.
Read ArticlePreparing a Biotechnology Commercial Strategy for the Board
Board-ready commercial strategy clarifies assumptions, capabilities, investment, risks and decision points—not a slide deck of tactics.
Read ArticleHow Commercial Strategy Influences Biotechnology Valuation
Investors increasingly ask whether a therapy can succeed commercially. Commercial readiness has become part of enterprise value—not only a post-approval activity.
Read ArticleMarket Opportunity Assessment for Emerging Biotech
A credible biotech market opportunity assessment challenges diagnosed population, reachability, adoption drivers and access—not epidemiology alone.
Read Article